Ann: Monepantel Selected for Entry into HEALEY ALS Platform Trial, page-53

For trehalose

Looks like its been used for numerous other disorders:

PHASE	STATUS	PURPOSE	CONDITIONS	COUNT	START DATE	WHY STOPPED
Unlock 175K+ rows when you subscribe.View sample data
4	Completed	Treatment	Corneal De-epithelialization/Photorefractive Keratectomy	1	somestatus View Sample Data	stop reason
4	Not Yet Recruiting	Prevention	Cataracts/Dry Eye Syndrome (DES)/Dry Eyes	1	somestatus View Sample Data	stop reason
4	Not Yet Recruiting	Treatment	Parkinson's Disease (PD)	1	somestatus View Sample Data	stop reason
3	Completed	Treatment	Bipolar Disorder (BD)/Depression, Bipolar	1	somestatus View Sample Data	stop reason
2	Completed	Treatment	Muscular Dystrophy, Oculopharyngeal (OPMD)

Trehalose is a low molecular weight disaccharide (0.342 kDa) that crosses the blood-brain barrier, stabilizes proteins and, importantly, activates autophagy, which is the process that clears pathologic material from cells. In animal models of ALS, treatment with trehalose delayed onset of disease, prolonged survival and preserved motor function and motor neurons in the spinal cord. Trehalose activates autophagy through the activation of Transcription Factor EB (TFEB), a key factor in lysosomal and autophagy gene expression. Activation of TFEB is an emerging therapeutic target for a myriad of diseases with pathologic accumulation of storage material. The drug is manufactured by Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases